

EQUITY RESEARCH

COMPANY ALERT

Company Alert

Evotec

Company Update: EVT101 development terminated, Price target adjusted



RATING
BUY (UNCHANGED)

TARGET PRICE
3.5 EUR (3.7 EUR)

HIGHLIGHTS

- Voluntary termination of phase II study by Roche
- Difficult recruitment and toxicology profile as reasons
- All rights for EVT101 and EVT103 returned to Evotec
- Further development depends on new partnership
- Fair share value reduced from EUR 3.70 to EUR 3.50

Roche and Evotec decided to terminate the phase II study with their NR2B sub-type specific NMDA antagonist EVT101 for the therapy of "treatment-resistant depression" (TRD). Reasons for the decision were difficulties to recruit patients under the current study protocol which might have led to inconclusive results. Despite up to 30% of patients belong to the group of TRD patients we suggest that the definition of this patient group is most challenging. In addition, the toxicology profile of EVT101 and the lack of a proper dosing scheme were additional reasons for the decision of the termination of the trial.

The study was conducted by Evotec but fully financed by Roche. Up to 100 patients were planned for the US trial and the first patient was recruited in Q3 2010. Data were expected by the end of 2011/early 2012 and Roche had a buy-back option of USD 65m. Roche has set up an additional clinical programme for TRD including a mGluR5 antagonist (RG7090) tested in phase II.

Evotec plans to outlicense the EVT100 family to other interested parties. The company confirmed that they do not intend to invest own money into the clinical development of the programme.

We adjust our NPV model for EVT101 and lower the fair value from EUR 1.25 per share to EUR 0.60 per share as we reduced the probability of success from 25% to 15% (representing a phase I status) and shift the expected launch date by 3 years to 2018. The possible USD 55m payment by Roche on positive phase II results had not been included in our model.


As a result the price target of Evotec calculated by DCF valuation (EUR 3.60 per share) , peer group valuation (EUR 2.40 per share) and NPV (EUR 1.12 per share) will be reduced by 5.5% from EUR 3.70 to EUR 3.50. We reiterate our rating to BUY the stock.

+++ Reuters: EVTG +++ Bloomberg: EVT GY +++

Current Price (XETRA (Germany); 2011-05-18; 12:13 pm).....2.81 EUR
 CLOSING PRICE (2011-05-17):.....2.97 EUR
 EXPECTED PERFORMANCE:.....24.6%
 MARKET CAPITALIZATION:.....351.01 EUR m
 ENTERPRISE VALUE:.....297.51 EUR m
 NUMBER OF SHARES:.....118.19 m
 FREE FLOAT:.....65.0%
 INDEX (WEIGHT):.....TecDAX (1.38%)
 AVG. DAILY TRADEVOL.:.....463,884
 ISIN:.....DE0005664809
 SECTOR:.....Biotechnology

KEY DATA (DEC)	2010	2011 E	2012E
Company figures in m EUR, per share data in EUR			
Sales	55.3	65.2	73.8
EBITDA	6.5	7.1	10.6
EBIT	1.7	2.4	7.7
Net profit	3.0	2.5	6.0
Free cash flow	-1.5	7.4	14.4
FCF yield	-0.5%	2.1%	4.1%
EPS	0.03	0.02	0.05
Dividend	0.00	0.00	0.00
EV / Sales	4.5	4.6	4.0
EV / EBITDA	38.6	41.7	28.1
EV / EBIT	145.8	126.1	38.8
P / E	106.6	143.5	57.7
P / BV	2.40	2.61	2.75
Dividend yield	0.0%	0.0%	0.0%

PRICE PERFORMANCE



Source: Evotec, LBBW Research, Thomson Reuters

UPCOMING EVENTS

June 16-11 AGM

Dr. Hanns Frohnmeyer
 Investment Analyst
 +49 711 127-76533
 Hanns.Frohnmeyer@LBBW.de

Appendix-1

1/2

Analyst's Certification

All of the views expressed in this research report accurately reflect the research analyst's personal views regarding the Subject Company. No part of analyst compensation was, is or will be, directly or indirectly related to the specific recommendations or views expressed in this research report.

Disclosures

Please Note

Important Disclosures Required by Regulators

1) LBBW or an associated enterprise of LBBW has made an agreement on the production of financial analyses relating to the issuer or its financial instruments.

Please Note

This research report and the information contained in this research report must not be distributed or reproduced, in whole or in part, in any form without the prior consent of Landesbank Baden-Württemberg ("LBBW") and only in accordance with the applicable laws in the relevant jurisdiction. Persons who gain access to this information must inform themselves about such applicable laws and have to comply with them.

This research report and the information contained therein is furnished and has been prepared solely for information purposes. It is not intended to be an inducement to engage in investment activity. It is furnished for your private information with the express understanding, which recipient acknowledges, that it is not an offer, recommendation or solicitation to buy, hold or sell, an invitation to subscribe for or purchase, or a means by which any security may be offered or sold.

LBBW does not accept any liability for the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions or the result obtained from the use of such information. The information in this report has been obtained from sources believed to be reliable. LBBW can not verify such information, however, and because of the possibility of human or mechanical error by the sources, LBBW or others, no representation is made that the information contained in this report is accurate in all material respects or complete. The statements contained herein are statements of our non-binding opinion, not statement of fact or recommendations to buy hold or sell any securities. Changes to assumptions may have a material impact on any performance detailed. Historic information on performance is not indicative of future performance. LBBW may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and LBBW is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. This report is intended only for and directed to persons sufficiently expert to understand the risks involved, namely market professionals. This publication does not replace personal consultancy. Prior to taking any investment decision you should contact your independent investment adviser for further and more up-to-date information on specific investment opportunities and for individual investment advice, regarding the appropriateness of investing in any securities or investment strategies discussed in this report.

Any security referred to herein may involve a high degree of risk, which may include principal, interest rate, index, currency, credit, political, liquidity, time value, commodity and market risk and is not suitable for all investors. The securities may experience sudden and large falls in their value causing losses equal to the original investment when that investment is realized. Any transaction entered into is in reliance only upon your judgment as to both financial, suitability and risk criteria. LBBW does not hold itself out to be an advisor in these circumstances, nor does any of its staff have the authority to do so.

United Kingdom

This document is issued in the United Kingdom by LBBW, London Branch. LBBW is authorised by the Bundesanstalt für Finanzdienstleistungsaufsicht (the "BaFin").

This document and the information contained in it constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 and the rules of the Financial Services Authority (the "FSA"). To the extent that this document is issued in the United Kingdom, it is directed exclusively at persons who are professional clients or eligible counterparties for the purposes of the FSA's Handbook of Rules and Guidance. The products and investment services to which this document relate are only available to the persons referred to above and other persons should not act or rely on it. Moreover, any investment or service to which this document relates is not intended for retail clients and will not be made available to retail clients.

This document is impartial investment research. This document has no regard to the specific investment objectives, financial need or situation or needs of any specific recipient and the investments discussed in this document may not be suitable for all recipients.

Appendix-1

2/2

LBBW, London Branch has effective organisational and administrative arrangements set up for the prevention and avoidance of conflicts of interest with respect to research recommendations, including information barriers. A copy of LBBW's investment research and conflict of interest policy is available on request from www.lbbw.de/lbbwde/1000005283-en.html

LBBW Research Rating-Systematics (absolute share rating system)

Rating definitions:

Buy:	Based on a time horizon of up to 12 months, we recommend that investors buy the stock.
Sell:	Based on a time horizon of up to 12 months, we recommend that investors sell the stock.
Hold:	We take a neutral view on the stock and, based on a time horizon of up to 12 months, do not recommend either a Buy or Sell.
Under review:	The rating is currently updated.
Suspended:	The evaluation of the company is currently not feasible.

Percentage of companies within this rating category

Buy:	54,2%
Sell:	5,0%
Hold:	39,3%
Under review:	0,5%
Suspended:	1,0%

Notes: Rating definitions prior to 6th April, 2009 were:

Buy: The price potential of the share is at least 10%. Hold: The price potential of the share is between 0% and 10%. Sell: A negative price performance of the share is expected. Ratings relate to a time horizon of up to 6 months.

For disclosures pertaining to recommendations or estimates made on securities research, please see the most recently published company report or visit our website at <http://www.lbbw.com/disclosures>

